SVB Securities analyst Marc Goodman maintained a Buy rating on Eliem Therapeutics (ELYM – Research Report) today and set a price target of $9.00. The company’s shares closed last Friday at $3.71, close to its 52-week low of $2.52.
According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.2% and a 46.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.
Eliem Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
See Insiders’ Hot Stocks on TipRanks >>
Eliem Therapeutics’ market cap is currently $98.57M and has a P/E ratio of -2.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Read More on ELYM:
- SVB Securities Thinks AC Immune SA’s Stock is Going to Recover
- G-III Apparel Group (GIII) Initiated with a Hold at Wells Fargo
- ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities
- Rivian Automotive (RIVN) Gets a Hold Rating from Wells Fargo
- Magnolia Oil & Gas (MGY) Receives a Rating Update from a Top Analyst
